Joshua Fitch, Senior Editor

“The significant rise in heat-related illnesses over the past decade underscores a growing public health concern that warrants further attention and action, said Taylor Merritt, MD, of the data presented at the AAP National Conference & Exhibition.

“Our study highlights the widespread nature of period poverty and the need for broad actions," said co-senior study author Meleah Boyle, PhD MPH at the 2024 AAP National Conference & Exhibition.

Infants were 22% less likely to develop asthma in early childhood if there were only fed breast milk during birth hospitalization, per a study presented at the 2024 AAP National Conference & Exhibition.

Our editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, previews some of the American Academy of Pediatrics National Conference & Exhibition, taking place right now in Orlando, Florida.

Eric Simpson, MD, MCR, FAAD, lead author of a recently-published article highlighting roflumilast cream 0.15%, joined us for a Q+A interview.

The needle-free option to treat type 1 allergic reactions, including anaphylaxis, was approved for adults and children who weigh 66 lbs or more on August 9, 2024.

With this acceptance, the federal agency has assigned a PDUFA date of May 22, 2025 for roflumilast foam (Zoryve) 0.3%.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to discuss potential advantages of LUM-201 as it goes through the clinical pipeline.

With this approval, FluMist becomes the first vaccine to prevent influenza that does not need to be administered by a health care provider.

The approval is indicated for adults and children aged 2 years and older, making arimoclomol (Miplyffa) the first drug approved by the FDA to treat NPC.

Those with inpatient food insecurity had an increased length of stay, as well as increased odds of readmission.

Infigratinib has also received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA.

Investigators found the association for higher BMI, increased obesity risk, and increased severe obesity risk.

Preadolescent sleep disturbances were linked to an increased risk of suicidal thoughts and behaviors in early adolescence, highlighting sleep as a key intervention target.

First-generation antihistamine prescriptions were linked to a 22% higher seizure risk in young children, especially those aged 6 to 24 months, according to recent findings.

According to findings, more consideration for individual differences in adverse experiences is needed for targeted interventions.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Findings from a newly-published study revealed that newborn metabolic profiles may identify infants at an increased risk for SIDS shortly after birth.

Linda DiMeglio, MD, MPH, joined us to discuss the “Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes."

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to talk PGHD and the role of the pediatrician when it comes to treatment.

Alan Percy, MD, discusses where the general provider comes in when treating Rett syndrome and prescribing trofinetide (Daybue).

Investigators concluded that findings suggest the need for improved public health messaging regarding fish intake guidelines for pregnant persons.

In this last episode, our panel discusses this patient population and the challenges around keeping them in the continuum of care.

Availability for the type 1 allergic reactions treatment approved by the FDA in August is expected later this month.

Alan Percy, MD, discussed what the FDA approval of trofinetide (Daybue) has meant to patients with Rett syndrome aged 2 years and older.

Screen time before bed did not impair sleep in children, but in-bed use demonstrated delayed sleep onset and reduced total sleep time.

Following the final ruling, requirements will be implemented beginning September 30, 2024.

The investigational MEK inhibitor has been assigned a Prescription Drug User Fee Act (PDUFA) date of February 28, 2025.